Начало › Колоректален рак › Колорадо › Denver
Клинични проучвания за Колоректален рак в Denver, CO
23 проучвания за Колоректален рак търсят участници в обекти в и около Denver (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
The Vanguard Study: Testing a New Way to Screen for Cancer
Набиране на участнициЗдравите доброволци са добре дошли
- Kaiser Permanente-Franklin, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- Rocky Mountain Cancer Center, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- AdventHealth Porter, Denver
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Набиране на участнициФаза 3
- Intermountain Health Cancer Center Saint Joseph, Denver
- Intermountain Health Saint Joseph Hospital - Research Office, Denver
- Intermountain Health Saint Joseph Hospital, Denver
- и още 3
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Набиране на участнициФаза 1/2
- Sarah Cannon Research Institute (SCRI), Denver
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Набиране на участнициФаза 3
- Rocky Mountain Cancer Centers, Denver
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Набиране на участнициФаза 3
- Rocky Mountain Cancer Centers, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Набиране на участнициФаза 1/2
- SCRI at HCA Health One, Denver
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Набиране на участнициФаза 1
- SCRI Denver, Denver
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Sarah Cannon Research Institute at HealthOne, Denver
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- Sarah Cannon Research Institute, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Набиране на участнициФаза 1
- Sarah Cannon Research Institue At Healthone, Denver
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Набиране на участнициФаза 3
- Rocky Mountain Cancer Centers, LLP, Denver
- Rocky Mountain Cancer Centers, LLP, Denver
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Набиране на участнициФаза 1
- Sarah Cannon Research Institute at HealthONE, Denver
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Набиране на участнициФаза 1
- Context Investigational Site, Denver
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Набиране на участнициФаза 2
- Rocky Mountain Cancer Center - Primary, Denver
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Набиране на участнициФаза 1
- Sarah Cannon Research Institute at HealthONE, Denver
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Набиране на участнициФаза 1/2
- SCRI - Denver, Denver
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Набиране на участнициФаза 1
- Sarah Cannon Cancer Institute at HealthONE, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- и още 1
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
Проучвания за Колоректален рак в други градове
- Houston, TX102 проучвания
- New York City, NY78 проучвания
- Nashville, TN69 проучвания
- Boston, MA63 проучвания
- Los Angeles, CA59 проучвания
- Arlington, VA52 проучвания
- St. Louis, MO50 проучвания
- San Antonio, TX46 проучвания
- Philadelphia, PA44 проучвания
- Grand Rapids, MI40 проучвания
- Baldwin Park, CA37 проучвания
- Chicago, IL34 проучвания
Други проучвания в Denver
- Метастатичен рак29 проучвания
- Рак на гърдата29 проучвания
- Рак на белия дроб с недребноклетъчен тип27 проучвания
- Множествен миелом27 проучвания
- Меланом19 проучвания
- Рак на простатата19 проучвания
- Рак (всички видове)18 проучвания
- Рак на яйчниците16 проучвания
- Рак на белия дроб16 проучвания
- Ендометриален рак15 проучвания
- Нон-Ходжкинов лимфом14 проучвания
- Рак на панкреаса13 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.